ArticleInternational journal of clinical oncology2026
Prediction of chemotherapy-induced nausea during irinotecan-based treatment based on prior oxaliplatin-induced symptoms in colorectal cancer.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with oxaliplatin- and irinotecan-based chemotherapy regimens. Because these agents are typically administered sequentially in colorectal cancer (CRC) treatment and have similar emetogenic risk, we assessed the real-world feasibility of predicting CINV during irinotecan treatment based on response to prior oxaliplatin.
methodsPatients with metastatic CRC who subsequently received an irinotecan-fluoropyrimidine-based regimen after prior treatment with an oxaliplatin-fluoropyrimidine-based regimen were retrospectively evaluated. Patients were divided into a control group (those who achieved total control [TC] during the first cycle of the oxaliplatin-based regimen) and a CINV-experience group (those who did not achieve TC during this cycle). The primary endpoint was TC rate during the delayed phase (24-120 h after treatment initiation) of the first irinotecan-based regimen.
resultsTC rate in the delayed phase was significantly lower in the CINV-experience group than that in the control group (31.8% and 81.8%, P < 0.0001, n = 44 in each group), which was also confirmed in the overall phase (0-120 h). The incidences of delayed and overall nausea and anorexia in the control and CINV-experience groups were 18.2% and 68.2% (P < 0.0001), 18.2% and 70.5% (P < 0.0001), and 25.6% and 61.4% (P = 0.001), respectively. These findings were confirmed in the propensity score-matched population and across different irinotecan or oxaliplatin dose levels.
conclusionsOur study suggests that patients who experienced CINV during prior oxaliplatin-based treatment are at an increased risk of developing symptoms during subsequent irinotecan-based treatment.
Indexed as
Identifiers
42390725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.